Intelligence Feed event · Capital · 2026-07-24

    Scribe Therapeutics Prices Upsized $128.7M IPO; Trading Starts Today

    Question

    Scribe Therapeutics Prices Upsized $128.7M IPO; Trading Starts Today

    Direct answer

    Scribe Therapeutics, a clinical-stage company focused on in vivo CRISPR technologies, has successfully navigated a volatile market to price an upsized IPO. The $128.7 million raise, coupled with a private placement from Sanofi, gives the company a significant runway for its development pipeline. The involvement of Sanofi as both a strategic partner and equity investor is a notable vote of confidence in Scribe's proprietary CRISPR platform. As trading commences today, the market will be watching for a 'pop' as a sign that the biotech sector's appetite for high-growth, high-risk clinical assets remains intact.

    Original publisher
    Market Ontology
    Evidence through
    2026-07-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Scribe Therapeutics Prices Upsized $128.7M IPO; Trading Starts Today”, revision 1, evidence through 2026-07-24. https://marketontology.com/market-events/2026-07-24/scribe-therapeutics-prices-upsized-128-7m-ipo-trading-starts-today-7a6bfb

    CAPITAL
    Scribe Therapeutics Prices Upsized $128.7M IPO; Trading Starts Today
    Scribe Therapeutics, a clinical-stage company focused on in vivo CRISPR technologies, has successfully navigated a volatile market to price an upsized IPO. The $128.7 million raise, coupled with a private placement from Sanofi, gives the company a significant runway for its development pipeline. The involvement of Sanofi as both a strategic partner and equity investor is a notable vote of confidence in Scribe's proprietary CRISPR platform. As trading commences today, the market will be watching for a 'pop' as a sign that the biotech sector's appetite for high-growth, high-risk clinical assets remains intact.
    SCTXXBI
    Impact
    60
    JUL 24
    SIG
    90%
    SCTXXBI
    Scribe Therapeutics Prices Upsized $128.7M IPO; Trading Starts Today
    Scribe Therapeutics, a clinical-stage company focused on in vivo CRISPR technologies, has successfully navigated a volatile market to price an upsized IPO. The $128.7 million raise, coupled with a private placement from Sanofi, gives the company a significant runway for its development pipeline. The involvement of Sanofi as both a strategic partner and equity investor is a notable vote of confidence in Scribe's proprietary CRISPR platform. As trading commences today, the market will be watching for a 'pop' as a sign that the biotech sector's appetite for high-growth, high-risk clinical assets remains intact.
    → New equity supply in the biotech sector → signal of risk appetite for CRISPR technologies.
    Impact
    Scribe Therapeutics, a clinical-stage company focused on in vivo CRISPR technologies, has successfully navigated a volatile market to price an upsized IPO. The $128.7 million raise, coupled with a private placement from Sanofi, gives the company a significant runway for its development pipeline. The involvement of Sanofi as both a strategic partner and equity investor is a notable vote of confidence in Scribe's proprietary CRISPR platform. As trading commences today, the market will be watching for a 'pop' as a sign that the biotech sector's appetite for high-growth, high-risk clinical assets remains intact.
    Affected
    SCTXXBI
    Transmission
    New equity supply in the biotech sector→signal of risk appetite for CRISPR technologies.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIWatch150.48 2026-07-24+0.07%-2.31%+10.13%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month